• Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.Abstract

    PURPOSE: The use of cytochrome P450 2D6-inhibiting drugs (CYP2D6 inhibitors) during tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the major active tamoxifen metabolite. Concomitant use of CYP2D6 inhibitors, such as slective serotonin reuptake inhibitors, as well as low tamoxifen adherence may negatively impact tamoxifen efficacy in patients with breast cancer

    Dezentje VO, van Blijder veen NJ, Gelder blom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ. J Clin Oncol. 2010 May 10; 28 (14): 2423-9.
  • New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System.Abstract

    BACKGROUND: Insight into co-morbidity and treatment effects is pivotal to improve quality of care for cancer patients. OBJECTIVES: To determine whether linkage of the Eindhoven Cancer Registry (ECR) and the PHARMO Record Linkage System (RLS) was tehnically feasible and to assess which patient-centric data would result from this linkage

    van Herk-Sukel MP, van dePoll-Franse LV, Lemmens VE, Vreugden hil G, Pruijt JF, Coebergh JW, Herings RM. Eur J Cancer. 2010 Jan; 46 (2): 395-404.
  • Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study.Abstract

    This case-control study investigates the potential chemoprophylactic properties of non-steroidal anti-inflammatory drugs (NSAIDs) on the incidence of cutaneous melanoma (CM). Data were extracted from the Dutch PHARMO pharmacy database and the PALGApathology database. Cases had a primary CM between 1991 and 2004, were >or=18 years, and were observed for 3 years in PHARMO before diagnosis

    Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. J Invest Dermatol. 2009 Nov; 129 (11): 2620-7.
  • Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Abstract

    A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate te possible association between use of ACEi and ARb and the risk of cutaneous melanoma

    Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Cancer Epidemiol. 2009 Nov; 33 (5): 391-5.
  • Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy.Abstract

    Recently, we showed there was a cumulative dose-dependent association between the use of estrogens and the incidence of cutaneous melanoma (CM). This association was shown for both oral contraceptives (OC) and hormonal replacement therapy (HRT). Soe in-vitro studies, however, have suggested a direct inhibitory effect on melanoma tumor growth

    Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Melanoma Res. 2009 Oct; 19 (5): 327-32.
  • Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study.Abstract

    BACKGROUND: Multiple studies showed conflicting results on the association between oral contraceptive (OC) use and the development of cutaneous melanoma (CM). We investigated the association between estrogen use and CM incidence. PATIENTS AND METHOS: Data from PHARMO Pharmacy database and PALGA, the pathology database in The Netherlands, were linked

    Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Ann Oncol. 2009 Feb; 20 (2): 358-64.
  • Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.Abstract

    BACKGROUND: This study evaluated trends in adjuvant systemic treatment among breast cancer patients and analyzed the factors on which treatment choice was based. PATIENTS AND METHODS: Patients diagnosed with early stage breast cancer in 1990-2006 wre selected from the registry of the Comprehensive Cancer Centre South (n= 8261)

    Sukel MP, van dePoll-Franse LV, Nieuwenhuijzen GA, Vreugden hil G, Herings RM, Coebergh JW, Voogd AC. Eur J Cancer. 2008 Jul 17; 1846-854.
  • Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.Abstract

    PURPOSE: To assess the incidence of cardiovascular events among breast cancer patients after chemotherapy. METHODS: Women >/=18 years with a breast tumour who received chemotherapy in 1992-2003 were selected from the PHARMO RLS. Chemotherapy with athracyclines, a combination of anthracyclines and taxanes or second line treatment with trastuzumab was classified as cardiotoxic

    Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beider beck AB, Coebergh JW, Herings RM. Pharmacoepidemiol Drug Saf. 2008 Jan; 17 (2): 125-134.
  • Medicinal cannabis in oncology.Abstract

    In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, iniiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product

    Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J. Eur J Cancer. 2007 Dec; 43 (18): 2638-44.
  • Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?.Abstract

    BACKGROUND: Statins show anticancer activity in melanoma cells. We investigated the association between statins and incidence and Breslow thickness of cutaneous melanoma (CM). METHODS: Data were used from PHARMO, a pharmacy database, and PALGA, a pthological database, in the Netherlands. Cases had a primary CM diagnosis between January 1st 1991 and December 14th 2004, were 18 years and had 3 years of follow up in PHARMO before CM diagnosis

    Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, Guchelaar HJ. Eur J Cancer. 2007 Nov; 43 (17): 2580-9.